Resources

Drug Discovery 2026 returns to ExCeL London from 14–15 October to celebrate 20 years of collaboration and inclusion. Keynote programme includes presentation from Dr Sam Barrell CBE and panel discussion with Dr Anne Phelan, Dr Jason Mellad, Prof Sir Mene Pangalos and Prof Raghib Ali OBE

LifeArc partners with Elpida Therapeutics to advance three gene therapies for ultra-rare neurodegenerative diseases in children

Poolbeg announces the positive outcome of a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA)

Firefinch Software sets out what instrument manufacturers need to know about building software that meets Good Manufacturing Practice (GMP) standards

King’s College London has spun out Korecyte Bio Ltd (Korecyte) and Cell and Gene Therapy Catapult (CGT Catapult) has enabled the spinout.

Poolbeg will present data on POLB 001 at the European Hematology Association Congress (EHA), taking place 11-14 June 2026 in Stockholm, Sweden.

Cell and Gene Therapy Catapult (CGT Catapult) will provide investment to Lir Therapeutics (Lir) to accelerate the development of nAAVigator, its AI-driven AAV capsid design platform.

CellCentric announces oversubscribed $220 Million Series D financing to advance pivotal trials of Inobrodib in Multiple Myeloma

Cytospire Therapeutics announces the closing of an oversubscribed £61 million ($83 million) Series A financing.

Stratosvir has received support from Cell and Gene Therapy Catapult (CGT Catapult), including investment from the Cross Catapult Investment Pilot.

The UK Medicines and Healthcare products Regulatory Agency has granted Clinical Trial Authorisation for the POLB 001 TOPICAL trial.

Semarion has raised $3.8 million USD (£2.9 million GBP)

In this blog, Jaime Eaton, reflects on this month's Community Connects series, bringing together diverse expertise to tackle the most pressing challenges in our sector.

Complement Therapeutics (CTx, has dosed the first patient in Opti-GAIN.

Abselion has appointed Dale Gordon as Chair of the Board of Directors.

A multiple myeloma candidate with a new mode of action is now in Phase 2 patient trials following positive Phase 1 results showing it kills cancer cells without toxicity to patients.

The Cell and Gene Therapy Catapult is launching a Technology Advisory Board to accelerate the UK’s leadership in advanced therapies.

BioLife Solutions has entered into a multi-year supply agreement with Qkine Limited.

Harness Therapeutics nominates HRN001 as its lead drug candidate for Huntington's disease and the formation of a clinical advisory board to support advancement towards clinical evaluation.